US03969F1093
© BusinessWire
12.12.2025
RCUS
LISTED
NYSE
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc....
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purcha...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2025
RCUS
LISTED
NYSE
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
News Preview
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in December:
8th Annual Everc...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
31.10.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
News Preview
Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 13,700,000 shares of its common stock at a price to the p...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
30.10.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
News Preview
Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stoc...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2025
RCUS
LISTED
NYSE
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a pipeline update on its clini...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
RCUS
LISTED
NYSE
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
News Preview
Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences, Inc. (NYSE:RCUS, “Arcus”) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International Nonproprietary Name; development code: AB521), an investigational small molecule HIF (Hypoxia Inducible Factor)-2α inhibitor, in Japan and certain o...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
RCUS
LISTED
NYSE
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
News Preview
Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced the first OS results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced unresectable or metastatic gastric, gastroes...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 60,300 shares of the Co...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
RCUS
LISTED
NYSE
Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced new monotherapy data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in late-line metastatic clear cell renal cell carcinoma (ccRCC...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 9,750 shares of the Com...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 19,300 shares of the...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
02.09.2025
RCUS
LISTED
NYSE
Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation
News Preview
Arcus Biosciences (NYSE:RCUS) announced today that it will host an in-person and virtual Investor Event for analysts and investors on Monday, October 6, 2025, beginning at 10:00 AM ET, in New York City.
The event will highlight new data for Arcus’s HIF-2a inhibitor casdatifan from the monotherapy cohorts of the Phase 1b ARC-20 trial in late-line...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2025
RCUS
LISTED
NYSE
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
News Preview
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in September:
Citi’s 2025 Biotech Back to School Conference
Date: W...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 4,200 shares of the Co...
Themefolio
Profiler
Peergroup
© BusinessWire
10.07.2025
RCUS
LISTED
NYSE
Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that quemliclustat, an investigational small molecule CD73 inhibitor, was granted orphan drug designation by the U.S. Food and Drug Administration...
Themefolio
Profiler
Peergroup
© BusinessWire
09.07.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 54,800 shares of the Co...
Themefolio
Profiler
Peergroup
© BusinessWire
24.06.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Comp...
Themefolio
Profiler
Peergroup
© BusinessWire
01.06.2025
RCUS
LISTED
NYSE
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented the first data for casdatifan plus cabozantinib in an oral presentation by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 13,400 shares of the...
Themefolio
Profiler
Peergroup
© BusinessWire
09.05.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 21,250 shares of th...
Themefolio
Profiler
Peergroup
© BusinessWire
06.05.2025
RCUS
LISTED
NYSE
Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a pipeline update on its clinical-stage investigational molecules across...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 39,750 shares of the...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
RCUS
LISTED
NYSE
Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that data from the ARC-20 study will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
RCUS
LISTED
NYSE
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update
News Preview
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Tuesday, May 6th, 2025 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company’s fina...
Themefolio
Profiler
Peergroup
© BusinessWire
09.04.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 16,960 shares of the...
Themefolio
Profiler
Peergroup
© BusinessWire
25.03.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted twelve new employees options to purchase a total of 42,920 shares of t...
Themefolio
Profiler
Peergroup
© BusinessWire
26.02.2025
RCUS
LISTED
NYSE
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
News Preview
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in March:
Leerink Global Healthcare Conference 2025
Date: Wednesday...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
RCUS
LISTED
NYSE
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a pipeline update on its clinical-stage investigationa...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 5,550 shares of the Co...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
RCUS
LISTED
NYSE
Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that Gilead’s time-limited exclusive option rights to casdatifan have expired. In addition, Arcus has announced the pricing of a $150 million comm...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
RCUS
LISTED
NYSE
Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced the pricing of an underwritten offering of 13,636,364 shares of its common stock at an offering price of $11.00 per share, for total gross proceeds...
Themefolio
Profiler
Peergroup
© BusinessWire
15.02.2025
RCUS
LISTED
NYSE
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Choueiri, Dana-Farber Cancer Ins...
Themefolio
Profiler
Peergroup
© BusinessWire
11.02.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that, in connection with the appointment of the Company’s new Chief Medical Officer, Richard Markus, M.D., Ph.D., the Compensation Committee of th...
Themefolio
Profiler
Peergroup
© BusinessWire
10.02.2025
RCUS
LISTED
NYSE
Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that data from the ARC-20 study will be presented in a rapid oral session at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (...
Themefolio
Profiler
Peergroup
© BusinessWire
24.01.2025
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 31,800 shares of the C...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
RCUS
LISTED
NYSE
Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D...
Themefolio
Profiler
Peergroup
© BusinessWire
24.12.2024
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 66,900 shares of the...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
RCUS
LISTED
NYSE
Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that Terry Rosen, Ph.D., chief executive officer, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The present...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2024
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 7,400 shares of the C...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2024
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 10,000 shares of th...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
RCUS
LISTED
NYSE
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
News Preview
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in December:
Evercore 7th Annual HealthCONx Conference
Date: Tuesda...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 14,100 shares of the C...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
RCUS
LISTED
NYSE
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the third quarter ended September 30, 2024, and provided a pipeline update on its clinical-stage investigational molecules —...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
RCUS
LISTED
NYSE
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plu...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
RCUS
LISTED
NYSE
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced four accepted abstracts at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place in Houston, Texas, November 6 – 10, 2024....
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2024
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 28,600 shares of the Co...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2024
RCUS
LISTED
NYSE
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today presented the first clinical activity data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Chouei...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2024
RCUS
LISTED
NYSE
Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update
News Preview
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Wednesday, November 6th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company’s fin...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 24,100 shares of the C...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
RCUS
LISTED
NYSE
Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced four accepted abstracts at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024, in Barcelo...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2024
RCUS
LISTED
NYSE
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced a clinical trial collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to evaluate casdatifan (AB521), Arcus’s investigational HIF-2a inhib...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2024
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 38,600 shares of the C...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2024
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 27,800 shares of the C...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2024
RCUS
LISTED
NYSE
Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported it has obtained a $250 million term loan facility from Hercules Capital, Inc. (NYSE: HTGC), a leader in customized debt financing for companies in li...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2024
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 21,100 shares of the...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2024
RCUS
LISTED
NYSE
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
News Preview
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September:
Morgan Stanley 22nd Annual Global Healthcare Conference...
Themefolio
Profiler
Peergroup
© BusinessWire
08.08.2024
RCUS
LISTED
NYSE
Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2024, and provided a pipeline update on its clinical-stage investigational molecules – target...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
